ArticleBJUI compass2026
Endoscopic management of upper tract urothelial carcinoma with laser ablation including Magneto pulse modulation.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the efficacy and safety of different laser technologies, including the new Holmium:YAG (Ho:YAG) Magneto pulse modulation, for the endoscopic ablation of upper tract urothelial carcinoma (UTUC). Materials and methods: Sixty-eight patients with UTUC from two centres were treated between February 2022 and June 2025. Three different lasers were used based on the available technology in each centre at the time of treatment: Ho:YAG with Vapor Tunnel pulse modulation (VT, Group A), thulium fibre laser (TFL, Group B) and Ho:YAG with Magneto pulse modulation (Mag, Group C). Intraoperative parameters, postoperative complications and recurrence rates were assessed. Results: Mean tumour size was 13.7 mm (range 5-30 mm). The overall mean operative time was 44.3 min. No intraoperative complications occurred. The overall rate of post-procedural complications was 19.1%. The most frequent complication was haematuria, affecting 10.3% of patients. The recurrence rate was 17.6% (12 out of 68 patients) with a mean time to recurrence of 3.3 months. At the last follow-up, 80.9% of patients were alive and free of disease, whereas 11.8% were alive with disease. Mortality due to urothelial carcinoma occurred in 1.5% of patients, whereas 5.8% of patients died from other causes. Conclusions: Endoscopic laser UTUC ablation is feasible and safe using both Ho:YAG and TFL, including the new Magneto pulse modulation technology. The low complication and recurrence rates support the use of this treatment in highly selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.